HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Tinidazole

HCID 5479
New reaction
Print

Completing data — refresh the page later to see the latest

Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
148159-84-6
Standard SMILES
CCS(=O)(=O)CCn1c([N+](=O)[O-])cnc1C
InChIKey
HJLSLZFTEKNLFI-UHFFFAOYSA-N
Molecular formula
C8H13N3O4S
Average molar mass
247.27 g/mol
Monoisotopic mass
247.0626769

Overview

Tinidazole is 1H-imidazole substituted at C-1 by a (2-ethylsulfonyl)ethyl group, at C-2 by a methyl group and at C-5 by a nitro group. It is used as an antiprotozoal, antibacterial agent. It has a role as an antiamoebic agent, an antiparasitic agent, an antiprotozoal drug and an antibacterial drug.

Names & identifiers

Preferred name
Tinidazole
IUPAC
1-(2-ethylsulfonylethyl)-2-methyl-5-nitroimidazole
English name
Tinidazole
Molecular formula
C8H13N3O4S
Molecular weight
247.27

Names & synonyms

tinidazole19387-91-8FasigynTrimonaseFasiginTricolam1-(2-(Ethylsulfonyl)ethyl)-2-methyl-5-nitro-1H-imidazoleSimplotanTinidazolSorquetanHaisigynTinidazolum
Show more names
TIXIAOZUO1-(2-(ethylsulfonyl)ethyl)-2-methyl-5-nitro-1h-imidazolpletibioshikcp12574
1-(2-ethylsulfonylethyl)-2-methyl-5-nitroimidazolePletilCP 12574timidazole1-[2-(Ethylsulfonyl)ethyl]-2-methyl-5-nitro-1H-imidazoleCP-125741-[2-(ethanesulfonyl)ethyl]-2-methyl-5-nitro-1H-imidazoleDTXSID4023676

Database identifiers

CAS
148159-84-6、19387-91-8
PubChem CID
5479
DTXSID
DTXSID4023676
ChEMBL
CHEMBL1220
ChEBI
CHEBI:63627
UNII
033KF7V46H
EC Number
243-014-4
Nikkaji
J2.752I

Properties

Computed structural propertiesFilling in

XLogP
-0.4
Topological polar surface area
106 Ų
Hydrogen bond donors
0
Hydrogen bond acceptors
5
Rotatable bonds
4
Heavy atoms
16
Formal charge
0
Complexity
345

Experimental & physicochemical properties

Drugs · 2 items

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals -> Antibiotics

LogP · 3 items

log Kow = -0.35

0.7

-0.38

Color/FormColorless crystals from benzene
Solubility · 2 items

3.03e+00 g/L

>37.1 [ug/mL] (The mean of the results at pH 7.4)

Human Drugs · 4 items

Breast Feeding; Lactation; Anti-Infective Agents; Antibacterial Agents; Antiprotozoal Agents; Nitroimidazoles

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Antiamoebic and antigiardiasis medicines

Animal DrugsPharmaceuticals -> Animal Drugs -> Approved in Taiwan
Melting Point · 3 items

127-128 °C

127-128 °C

127 - 128 °C

Physical Description

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 4 items

Warning

H312 (56.8%): Harmful in contact with skin [Warning Acute toxicity, dermal]

P203, P261, P271, P280, P302+P352, P304+P340, P317, P318, P321, P362+P364, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 74 reports by companies from 7 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Hazard information

Regulatory InformationTinidazole: Does not have an individual approval but may be used under an appropriate group standard
Other Safety InformationIMAP assessments - 1H-Imidazole, 1-[2-(ethylsulfonyl)ethyl]-2-methyl-5-nitro-: Environment tier I assessment
FDA Requirements · 1 item

The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription drug products, incl tinidazole, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act.

Special ReportsManes G, Balzano A.; Tinidazole: From Protozoa to Helicobacter Pylori--The Past, Present and Future of a Nitroimidazole with Peculiarities; Expert Rev Anti Infect Ther 2 (5): 695-705 (2004)
Hazard Classes and CategoriesAcute Tox. 4 (56.8%)

Safety & protection

Disposal Methods · 1 item

Chemistry & industry

Pharmacology

ATC Code · 6 items

J01XD02

P - Antiparasitic products, insecticides and repellents

J - Antiinfectives for systemic use

G - Genito urinary system and sex hormones

QG - Genito urinary system and sex hormones

QJ - Antiinfectives for systemic use

Protein BindingPlasma protein binding of tinidazole is 12%.
Pharmacodynamics · 1 item

Tinidazole is a synthetic antiprotozoal agent. Tinidazole demonstrates activity both in vitro and in clinical infections against the following protozoa: <i>Trichomonas vaginalis</i>, <i>Giardia duodenalis</i> (also termed <i>G. lamblia</i>), and <i>Entamoeba histolytica</i>. Tinidazole does not appear to have activity against most strains of vaginal lactobacilli.

Mechanism of Action · 2 items

Tinidazole is a prodrug and antiprotozoal agent. The nitro group of tinidazole is reduced in <i>Trichomonas</i> by a ferredoxin-mediated electron transport system. The free nitro radical generated as a result of this reduction is believed to be responsible for the antiprotozoal activity. It is suggested that the toxic free radicals covalently bind to DNA, causing DNA damage and leading to cell death. The mechanism by which tinidazole exhibits activity against <i>Giardia</i> and <i>Entamoeba</i> species is not known, though it is probably similar.

The nitro group of tinidazole is reduced by cell extracts of Trichomonas. As a result of this reduction a free nitro radical is generated which may be responsible for the antiprotozoal activity. The mechanism by which tinidazole exhibits activity against Giardia and Entamoeba species is not known.

Biological Half-Life · 2 items

The elimination half-life is 13.2±1.4 hours and the plasma half-life is 12 to 14 hours.

Elimination: 13.2 (+ or - 1.4) hours. Plasma: approximately 12 to 14 hours.

Metabolism/Metabolites · 2 items

Hepatic, mainly via CYP3A4. Tinidazole, like metronidazole, is significantly metabolized in humans prior to excretion. Tinidazole is partly metabolized by oxidation, hydroxylation and conjugation. Tinidazole is the major drug-related constituent in plasma after human treatment, along with a small amount of the 2-hydroxymethyl metabolite.

Related reactions

3 records
New reaction record
HRID 125211 reaction equation
HRID 125211As product
HRID 681391 reaction equation
HRID 681391As product
HRID 971469 reaction equation
HRID 971469As product

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Solid
Collision Cross Section149.7 Ų [M+H]+ [CCS Type: TW; Method: calibrated with Waters Major Mix]

Physicochemical properties

Melting point
118 · 118-120C
Boiling point
528.4 · 528.4±30.0 °C(Predicted)
Density
1.4338 · 1.4338 (rough estimate)
refractive index
1.632 · 1.6320 (estimate)
storage temp.
Sealed in dry,Room Temperature
solubility
Practically insoluble in water, soluble in acetone and in methylene chloride, sparingly soluble in methanol.
pka
2.3 · 2.30±0.34(Predicted)
form
Solid
color
Off-White to Pale Yellow
λmax
317 nm · 317nm(H2O)(lit.)
Merck
14 · 14,9447
BRN
618182 · 618182
Henry's Law Constant
1.9 · 1.9×105 mol/(m3Pa) at 25℃, HSDB (2015)
Stability
Stable. Incompatible with strong oxidizing agents.
Major Application
forensics and toxicologypharmaceutical (small molecule)
InChI
1S/C8H13N3O4S/c1-3-16(14,15)5-4-10-7(2)9-6-8(10)11(12)13/h6H,3-5H2,1-2H3
InChIKey
HJLSLZFTEKNLFI-UHFFFAOYSA-N
SMILES
CCS(=O)(=O)CCn1c(C)ncc1[N+]([O-])=O
CAS DataBase Reference
19387 · 19387-91-8(CAS DataBase Reference)
NCI Dictionary of Cancer Terms
tinidazole
FDA UNII
33 KF7V46H · 033KF7V46H
NCI Drug Dictionary
Fasigyn
ATC code
1 XD02,P01AB02 · J01XD02,P01AB02
UNSPSC Code
41116107 · 41116107
NACRES
24 · NA.24
Protein binding
8 · 8-12%
Excreted unchanged in urine
20 · 20-25%
Volume of distribution
0.61 · 0.61-0.67(L/kg)
Biological half-life
12 · 12-14 / Unchanged
Symbol(GHS)
7 · GHS07,GHS08
Signal word
Warning
Hazard statements
312 · H312+H332-H341-H351
Precautionary statements
201 · P201-P202-P280-P302+P352+P312-P304+P340+P312-P308+P313
PPE
95 · dust mask type N95 (US), Eyeshields, Faceshields, Gloves
Hazard Codes
Xn
Risk Statements
20 · 20/21/22-40
Safety Statements
26 · 26-36
WGK Germany
3 · 3
RTECS
6255000 · NI6255000
HS Code
2933290000 · 2933290000
Storage Class
11 · 11 - Combustible Solids
Hazard Classifications
4 DermalAcute · Acute Tox. 4 DermalAcute Tox. 4 InhalationCarc. 2Muta. 2
Hazardous Substances Data
19387 · 19387-91-8(Hazardous Substances Data)
Toxicity
50 in · LD50 in mice (mg/kg): >3600 orally; >2000 i.p. (Miller)

SRP: The most favorable course of action is to use an alternative chemical product with less inherent propensity for occupational exposure or environmental contamination. Recycle any unused portion of the material for its approved use or return it to the manufacturer or supplier. Ultimate disposal of the chemical must consider: the material's impact on air quality; potential migration in soil or water; effects on animal, aquatic, and plant life; and conformance with environmental and public health regulations.

Toxicology

Interactions · 5 items

Cholestyramine may decrease oral bioavailability; separate dosing of cholestyramine and tinidazole is recommended.

Effects may be enhanced when these agents /coumarin anticoagulants/ are used concurrently with tinidazole resulting in prolongation of prothrombin time; dosage of oral anticoagulants may need to be adjusted during tinidazole therapy and up to 8 days after discontinuation.

It is recommended that these substances /ethyl alcohol, ethanol-containing preparations, propylene glycol/ not be used concurrently with tinidazole, or for 3 days following tinidazole therapy; abdominal cramps, nausea, vomiting, headache, or flushing may occur.

Concomitant administration /of intravenous phenytoin or intravenous fosphenytoin/ with tinidazole increases half life and decreases clearance of phenytoin.

For more Interactions (Complete) data for TINIDAZOLE (11 total), please visit the HSDB record page.

Hepatotoxicity · 1 item

Tinidazole is typically given for a few days only, but serum enzyme elevations have been reported with its use, and serum enzyme elevations during therapy is listed as a possible adverse event in the product label. Tinidazole is also capable of causing anaphylactic and allergic reactions including urticaria, angioedema and bronchospasm, reactions which can be associated with minor serum enzyme elevations. Tinidazole, despite considerable use worldwide, has not been linked convincingly to instances of clinically apparent liver injury with jaundice.

Environmental Fate · 3 items

TERRESTRIAL FATE: Based on a classification scheme(1), an estimated Koc value of 15(SRC), determined from a log Kow of -0.35(2) and a regression-derived equation(3), indicates that tinidazole is expected to have very high mobility in soil(SRC). The estimated pKa of tinidazole is 4.7 (sp2 hybridized imidazole nitrogen)(4), indicating that this compound will exist partially as a cation in the environment under acidic conditions and cations generally have lower mobility in soil than their neutral counterparts(5). Volatilization of tinidazole from moist soil surfaces is not expected to be an important fate process(SRC) because cations do not volatilize and based on an estimated Henry's Law constant of 5.2X10-11 atm-cu m/mole(SRC), calculated using a fragment constant estimation method(6). Tinidazole is not expected to volatilize from dry soil surfaces(SRC) based upon an estimated vapor pressure of 2.7X10-7 mm Hg(SRC), determined from a fragment constant method(7). Biodegradation data were not available(SRC, 2005).

AQUATIC FATE: Based on a classification scheme(1), an estimated Koc value of 15(SRC), determined from a log Kow of -0.35(2) and a regression-derived equation(3), indicates that tinidazole is not expected to adsorb to suspended solids and sediment(SRC). The estimated pKa of tinidazole is 4.7 (sp2 hybridized imidazole nitrogen)(3), indicating that this compound will exist partially as a cation in the environment under acidic conditions and cations generally adsorb more strongly to sediment than their neutral counterparts(4). Volatilization from water surfaces is not expected(5) because cations do not volatilize and based upon an estimated Henry's Law constant of 5.2X10-11 atm-cu m/mole(SRC), developed using a fragment constant estimation method(6). According to a classification scheme(7), an estimated BCF of <1(SRC), from the measured log Kow(2) and a regression-derived equation(8), suggests the potential for bioconcentration in aquatic organisms is low(SRC). Biodegradation data were not available(SRC, 2005).

ATMOSPHERIC FATE: According to a model of gas/particle partitioning of semivolatile organic compounds in the atmosphere(1), tinidazole, which has an estimated vapor pressure of 2.7X10-7 mm Hg at 25 °C(SRC), determined from a fragment constant method(2), is expected to exist solely in the particulate phase in the ambient atmosphere. Particulate-phase tinidazole may be removed from the air by wet or dry deposition(SRC). Tinidazole does not contain chromophores that absorb at wavelengths >290 nm and therefore is not expected to be susceptible to direct photolysis by sunlight(SRC).

Milk ConcentrationsTinidazole is distributed into breast milk at concentrations similar to those in serum.
Soil Adsorption/Mobility · 1 item

The Koc of tinidazole is estimated as 15(SRC), using a log Kow of -0.35(1) and a regression-derived equation(2). According to a classification scheme(3), this estimated Koc value suggests that tinidazole is expected to have very high mobility in soil. The estimated pKa of tinidazole is 4.7 (sp2 hybridized imidazole nitrogen)(4), indicating that this compound will partially exist in the cation form in the environment under acidic conditions and cations generally have lower mobility in soil than their neutral counterparts(5).

Artificial Pollution SourcesTinidazole's production and use as an antiprotozoal agent(1) may result in its release to the environment through various waste streams(SRC).
Drug Induced Liver Injury · 6 items

Drug Induced Liver Injury Rank (DILIrank 2.0)

Tinidazole

vLess-DILI-concern

3

Adverse reactions

DOI:10.1016/j.drudis.2016.02.015

Environmental Bioconcentration · 1 item

An estimated BCF of <1 was calculated for tinidazole(SRC), using a log Kow of -0.35(1) and a regression-derived equation(2). According to a classification scheme(3), this BCF suggests the potential for bioconcentration in aquatic organisms is low(SRC).

Volatilization from Water/Soil · 1 item

The Henry's Law constant for tinidazole is estimated as 5.2X10-11 atm-cu m/mole(SRC) using a fragment constant estimation method(1). The estimated pKa of tinidazole is 4.7 (sp2 hybridized imidazole nitrogen)(2), indicating that this compound will exist partially as a cation in the environment under acidic conditions. Based on this Henry's Law constant and the fact that cations do not volatilize, tinidazole is expected to be essentially nonvolatile from moist soil and water surfaces(3). Tinidazole is not expected to volatilize from dry soil surfaces(SRC) based upon an estimated vapor pressure of 2.7X10-7 mm Hg(SRC), determined from a fragment constant method(4).

Non-Human Toxicity Excerpts · 5 items

/LABORATORY ANIMALS: Chronic Exposure or Carcinogenicity/ Metronidazole, a chemically-related nitroimidazole, has been reported to be carcinogenic in mice and rats but not hamsters. In several studies metronidazole showed evidence of pulmonary, hepatic and lymphatic tumorigenesis in mice and mammary and hepatic tumors in female rats. Tinidazole carcinogenicity studies in rats, mice or hamsters have not been reported.

/LABORATORY ANIMALS: Developmental or Reproductive Toxicity/ Embryo-fetal developmental toxicity studies in pregnant mice indicated no embryo-fetal toxicity or malformations at the highest dose level of 2,500 mg/kg.

/LABORATORY ANIMALS: Developmental or Reproductive Toxicity/ Sixty-day fertility study done in male rats given doses (600 mg/kg/day) of tinidazole, resulting in reduced fertility and produced testicular histopathology. Spermatogenic effects resulted from dose levels of 300 and 600 mg/kg/day, while the no observed adverse effects dose level was 100 mg/kg/day. These effects are characteristic of agents in the 5-nitroimidazole class.

/LABORATORY ANIMALS: Developmental or Reproductive Toxicity/ In a study with pregnant rats a slightly higher incidence of fetal mortality was observed at a maternal dose of 500 mg/kg. No biologically relevant neonatal developmental effects were observed in rat neonates following maternal doses as high as 600 mg/kg.

/GENOTOXICITY/ Tinidazole was found to be mutagenic in the TA100, S. typhimurium testere strain both with and without the metabolic activation system and was not mutagenic in the TA98 strain. However mutagenicity results were mixed both positive and negative in the TA1535, 1537, and 1538 strains. Tinidazole was also positive in a tester strain of Klebsiella pneumonia and positive for in vivo genotoxicity in the mouse micronucleus assay. Tinidazole was negative for mutagenicity in a mammalian cell culture system with Chinese hamster lung V79 cells and negative for genotoxicity in the Chinese hamster ovary sister chromatid exchange assay.

Environmental Abiotic Degradation · 1 item

Tinidazole is not expected to undergo hydrolysis in the environment due to the lack of functional groups that hydrolyze under environmental conditions(1). Tinidazole does not contain chromophores that absorb at wavelengths >290 nm and therefore is not expected to be susceptible to direct photolysis by sunlight(SRC).

Probable Routes of Human Exposure · 1 item

Occupational exposure to tinidazole may occur through inhalation and dermal contact with this compound at workplaces where tinidazole is produced or used. Exposure to tinidazole among the general population may be limited to those administered this substance as a drug. (SRC)

Regulatory information

FDA Requirements · 1 item

The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription drug products, incl tinidazole, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act.

Safety data

PPE
dust mask type N95 (US), Eyeshields, Faceshields, Gloves
wgk
3
rtecs
NI6255000
hs_code
2933290000
Toxicity
LD50 in mice (mg/kg): >3600 orally; >2000 i.p. (Miller)
risk_code
20/21/22-40
Signal word
Warning
Symbol(GHS)
GHS07,GHS08
hazard_code
Xn
safety_code
26-36
Storage Class
11 - Combustible Solids
Hazard statements
H312+H332-H341-H351
Hazard Classifications
Acute Tox. 4 DermalAcute Tox. 4 InhalationCarc. 2Muta. 2
Precautionary statements
P201-P202-P280-P302+P352+P312-P304+P340+P312-P308+P313
Hazardous Substances Data
19387-91-8(Hazardous Substances Data)

Tinidazole, like metronidazole, is significantly metabolized in humans prior to excretion. Tinidazole is partly metabolized by oxidation, hydroxylation and conjugation. Tinidazole is the major drug-related constituent in plasma after human treatment, along with a small amount of the 2-hydroxymethyl metabolite. Tinidazole is biotransformed mainly by CYP3A4. In an in vitro metabolic drug interaction study, tinidazole concentrations of up to 75 ug/mL did not inhibit the enzyme activities of CYP1A2, CYP2B6, CYP2C9, CYP2D6, CYP2E1 and CYP3A4.

FDA Pharmacological Classification · 6 items

033KF7V46H

TINIDAZOLE

Established Pharmacologic Class [EPC] - Nitroimidazole Antimicrobial

Chemical Structure [CS] - Nitroimidazoles

Tinidazole is a Nitroimidazole Antimicrobial.

TINIDAZOLE

MeSH Pharmacological Classification · 3 items

Highly reactive chemicals that introduce alkyl radicals into biologically active molecules and thereby prevent their proper functioning. Many are used as antineoplastic agents, but most are very toxic, with carcinogenic, mutagenic, teratogenic, and immunosuppressant actions. They have also been used as components in poison gases.

Agents used to treat trichomonas infections.

Substances that inhibit the growth or reproduction of BACTERIA.

Absorption, Distribution and Excretion · 6 items

Rapidly and completely absorbed under fasting conditions. Administration with food results in a delay in Tmax of approximately 2 hours and a decline in Cmax of approximately 10% and an AUC of 901.6 ± 126.5 mcg hr/mL.

Tinidazole crosses the placental barrier and is secreted in breast milk. Tinidazole is excreted by the liver and the kidneys. Tinidazole is excreted in the urine mainly as unchanged drug (approximately 20-25% of the administered dose). Approximately 12% of the drug is excreted in the feces.

50 L

Tinidazole is distributed into virtually all tissues and body fluids. Tinidazole also crosses the blood-brain barrier, placental barrier and is distributed into breast milk. Volume of distribution (VolD): about 50 L.

Under fasted conditions tinidazole is rapidly and completely absorbed. Administration with food resulted in a delay in Tmax of approximately 2 hours and a decline in Cmax of approximately 10% and an AUC of 901.6 + or - 126.5 ug hr/mL.

Time to peak concentration: 1.6 (+ or - 0.7 hours)

Cellular LocationsCytoplasm

Uses & manufacturing

Uses · 3 items

MEDICATION

Antitrichomonal Agents

Antiprotozoal and antibacterial activity

Methods of ManufacturingSynthesis: heating 2-methyl-5-nitroimidazole with 2-ethylsulfonylethyl-4-toluenesulfonate for 4 h
Formulations/PreparationsOral: Tablets, film-coated: 250 mg Tindamax (scored), (Presutti); 500 mg Tindamax (scored), (Presutti).
Use ClassificationPharmaceuticals -> Animal Drugs -> Approved in Taiwan
Applications · 4 items

UsesAntiprotozoal (Trichomonas, Giardia); antiamebic; antibacterial.

Usesanticonvulsant

Usesanti-ulcerative

UsesFor the treatment of trichomoniasis caused by T. vaginalis in both female and male patients. Also for the treatment of giardiasis caused by G. duodenalis in both adults and pediatric patients older than three years of age and for the treatment of intestin

Upstream & downstream products

Upstream raw materials

Tosyl chloride2-(ETHYLSULFONYL)ETHANOL2-Methyl-5-nitroimidazole
Additional notes · 1 item

DefinitionChEBI: Tinidazole is 1H-imidazole substituted at C-1 by a (2-ethylsulfonyl)ethyl group, at C-2 by a methyl group and at C-5 by a nitro group. It is used as an antiprotozoal, antibacterial agent. It has a role as an antiprotozoal drug, an antibacterial drug, an antiparasitic agent and an antiamoebic agent.